FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib
Financing extends Company’s cash runway beyond important clinical milestones anticipated beginning in 2H25, supporting the ongoing execution of the FORTE Master Protocol evaluating plixorafenib as a monotherapy in three distinct patient populations PHILADELPHIA–(BUSINESS WIRE)–FORE Biotherapeutics,…